Please login to the form below

Not currently logged in
Email:
Password:

Exviera

This page shows the latest Exviera news and features for those working in and with pharma, biotech and healthcare.

Gilead’s hepatitis C sales start to slide – the question is how quickly?

Gilead’s hepatitis C sales start to slide – the question is how quickly?

UK. New entrants such as AbbVie's Viekirax (paritaprevir, ombitasvir and ritonavir) and Exviera (dasabuvir) and Merck &Co's Zepatier (elbasvir/grazoprevir) have also played a role, although Gilead maintains that

Latest news

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • AbbVie: New firm, new thinking AbbVie: New firm, new thinking

    However, AbbVie is set to make an impact in 2015 with the launch of its own interferon-free regimen for hepatitis C, a combination of Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics